Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes the company as currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event at the end. The transcript includes statements about various programs, but we need to find a coherent situation where all three conditions are met. Key candidates: aflibercept 8 mg launch, Dupixent COPD readout, oncology pipeline, etc. But the question is about a waiting period where the company is paying now for something not yet earning, and the end is a specific near-dated event. Look at the transcript: Len mentions "We are preparing for a potential U.S. launch for aflibercept 8 milligrams in late August given prescribers decade plus experience with EYLEA." That is a future event. But is the company currently paying for something? They have R&D costs, but that's normal. The launch is not yet earning, but they are not explicitly saying they are bearing costs for that specific launch. They have manufacturing expansion, but that's general. Another candidate: the next-generation COVID antibody. George says "we have identified a potent broadly neutralizing COVID-19 antibody... We plan to initiate clinical trials to test this antibody this year." That's early, not a near-dated earning event. What about the Libtayo transaction? They took on full costs, but that's already earning. The question asks: "does management describe the company as CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET" with three conditions. We need to see if management explicitly frames a current cost with a specific near-term payoff. Look at Bob Landry's guidance: R&D expense increase due to late-stage pipeline, etc. But that's general. Perhaps the most fitting is the aflibercept 8 mg launch. They have submitted BLA, expect approval late August, and are preparing for launch. But are they paying for something now? They have manufacturing, but that's ongoing. They don't say "we are incurring costs specifically for this launch that will only be recouped after launch." They do mention "we are preparing" but not that they are bearing a burden. Another possibility: the expansion of manufacturing facilities. Bob says capital expenditures for expansion of manufacturing facilities, including fill/finish facility. That is a cost now for future benefit.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.